Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia (APL0618)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03751917|
Recruitment Status : Recruiting
First Posted : November 23, 2018
Last Update Posted : October 8, 2020
The therapeutic advantage of the association of ATRA + Arsenic Trioxide is more favorable and manageable as compared to ATRA + chemotherapy. Nevertheless, at present, there is not enough information on the incidence of long-term side effects.
This study, as well as other similar studies conducted around Europe, will focus on following patients treated with this therapy on a long-term basis.
Once all studies in Europe will be concluded, all data will be analyzed together.
|Condition or disease||Intervention/treatment|
|Acute Promyelocytic Leukemia||Drug: Arsenic Trioxide|
Considering the clear therapeutic advantage associated with ATRA+ATO combination therapy and the more favorable and overall manageable safety profile compared to ATRA+chemotherapy, the benefits of the combination in the first-line indication do appear to overweigh the risks.
However, no information regarding the actual adverse event (AE) incidence and the long-term toxicity of ATRA+ATO is available at present and therefore, as a postmarketing commitment, TEVA (the Company holding the Marketing Authorisation of Trisenox® (Arsenic trioxide)) is setting up a long-term safety cohort study of Trisenox in newly diagnosed low- to intermediate-risk APL patients retrospectively analyzing data from APL disease registries all around Europe.
As a result, this observational study is part of the retrospective PASS Study (A Post-Authorisation Long-Term Retrospective Safety Cohort Study of Arsenic Trioxide in First Line Low-to Intermediate-Risk Acute Promyelocytic Leukaemia Patients) that will use data from multinational APL disease registries in Europe. The present study will focus on Italian patients.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||A Long-Term Retrospective and Prospective Safety Study of Arsenic Trioxide in Patients With Newly Diagnosed, Low- to Intermediate-Risk Acute Promyelocytic Leukemia (APL)|
|Actual Study Start Date :||April 14, 2020|
|Estimated Primary Completion Date :||December 2024|
|Estimated Study Completion Date :||December 2024|
The study will be conducted using multinational data from disease registries for APL. The study participants will consist of patients with newly diagnosed, low-to intermediate-risk APL.
Drug: Arsenic Trioxide
This is an observational study. Patients who have received or are receiving all trans retinoic acid (ATRA) + Arsenic Trioxide will be followed and analyzed.
Other Name: ATRA+ATO
- Number of grade III/IV (Common Terminology Criteria for Adverse Events (CTCAE) v4.03) adverse events of special interest (AESI). [ Time Frame: At a maximum of 5 years from study entry ]AESI are, among others: differentiation syndrome, creatinine, bilirubin, neurotoxicity, aspartate amino transferase/alanine amino transferase (ASAT/ALAT) ratio, haemorrhage, sepsis, QTc prolongation, cardiac events including congestive heart failure (CHF).
- Number of unexpected serious adverse events (SAEs). [ Time Frame: At a maximum of 5 years from study entry ]Including grading and relationship as documented in the study.
- Number of patients developing secondary malignancies. [ Time Frame: At a maximum of 5 years from study entry ]
- Number of patients developing therapy-related myelodysplastic syndrome (tMDS). [ Time Frame: At a maximum of 5 years from study entry ]
- Number of patients developing acute myeloid leukemia (tAML). [ Time Frame: At a maximum of 5 years from study entry ]
- Number of patients who die. [ Time Frame: At a maximum of 5 years from study entry ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03751917
|Contact: Paola Fazi||+39 firstname.lastname@example.org|
|Contact: Enrico Crea||+39 email@example.com|